<DOC>
	<DOCNO>NCT02835079</DOCNO>
	<brief_summary>Duchenne muscular dystrophy ( DMD ) progressive devastate disease affect mainly boy , incidence 1:3,500 live birth . The pathology DMD result non-repaired muscle damage lead muscle-tissue replacement scar tissue , process know fibrosis . Currently , effective treatment disease . The therapy offer boy steroid slightly delay disease progression . The boy lose ability walk around age 12 , die 4th decade life severe heart lung problem . In study investigator test efficacy Tamoxifen treatment ambulatory DMD boys . Tamoxifen drug use palliative treatment breast cancer patient outstanding safety profile . In addition , Tamoxifen test past boy , pediatric indication , show excellent safety side effect . Tamoxifen test study , therapy DMD , follow reason : ( ) show anti-fibrotic effect multiple in-vivo system ; ( ii ) assist repair damage muscle . In word , Tamoxifen expect synergistic effect DMD patient , due dual mechanism action . Indeed , Tamoxifen show significant beneficial effect mdx mouse model DMD . Also , small compassionate cohort 3 boy , treat 6 month Tamoxifen , yield encouraging result .</brief_summary>
	<brief_title>Treatment Effect Tamoxifen Patients With DMD</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Ambulatory Non Ambulatory</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Duchenne Tamoxifen</keyword>
</DOC>